11/4/2019 An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.

dney disease. - PubMed - NCBI

PubMed

Format: Abstract

J Nephrol. 2008 Mar-Apr;21(2):213-20.

An oral adsorbent, AST-120, combined with a low-protein diet and

RAS blocker, for chronic kidney disease.
Yorioka N1, Kiribayashi K, Naito T, Ogata S, Yokoyama Y, Kyuden Y, Ogawa T, Wada K, Hayashi K, Hirabayashi
A.

Author information
1 Department of Advanced Nephrology, Graduate School of Biomedical Sciences, Hiroshima
University, Hiroshima, Japan. nyorioka@hiroshima-u.ac.jp

Abstract
BACKGROUND: A low-protein diet and treatment with renin-angiotensin system (RAS) blockers can
delay the progression of chronic kidney disease (CKD). The oral adsorbent AST-120 (Kremezin) has
a renoprotective effect by reducing serum levels of uremic toxins. We investigated the influence of
AST-120 on the preservation of renal function in patients with CKD.
METHODS: Twenty-eight patients were randomized to 2 groups: 15 patients receiving 6.0 g of AST-
120 daily for 12 months plus a low-protein diet and RAS blocker therapy (group A) and 13 patients
who were not given AST-120 (group B). All of them had shown progressive deterioration of renal
function with basal treatment. Mean baseline serum creatinine level (+/- standard deviation) was 2.4
+/- 0.8 mg/dL in group A and 2.7 +/- 0.8 mg/dL in group B. There were no significant differences in
background parameters before AST-120 therapy.
RESULTS: The change in the estimated glomerular filtration rate (eGFR) was significantly smaller in
group A than in group B. The change was also significantly smaller in patients with a baseline serum
creatinine <2.4 mg/dL and in patients with rapid progression. After 12 months, the slope of the eGFR
curve was significantly less steep compared with baseline in group A (-1.77 vs. -0.52 ml/min per
month), but there was no significant change in group B. The slope was also significantly less steep in
patients with rapid progression.
CONCLUSIONS: Adding AST-120 to a low-protein diet and RAS blocker therapy may delay the
deterioration of chronic renal failure, especially in patients with early or rapid progression.

PMID: 18446716
[Indexed for MEDLINE]

https://www.ncbi.nlm.nih.gov/pubmed/18446716 1/2
11/4/2019 An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease. - PubMed - NCBI

Publication type, MeSH terms, Substances

LinkOut - more resources

https://www.ncbi.nlm.nih.gov/pubmed/18446716 2/2